{
    "clinical_study": {
        "@rank": "154708", 
        "acronym": "GZA", 
        "arm_group": [
            {
                "arm_group_label": "Aubagio MRI", 
                "description": "Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire."
            }, 
            {
                "arm_group_label": "Healthy controls", 
                "description": "Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire."
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum to be retained."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study will evaluate the effects of Aubagio on changes in the brain using MRI."
        }, 
        "brief_title": "Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who take Aubagio will have an MRI, eye test, have blood taken, and complete a\n      questionnaire on environmental risk factors to evaluate changes in the brain and on disease\n      progression. A healthy control group will also complete the same testing regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects aged 18-65\n\n          -  Clinically definite MS according to the Polman criteria, 52\n\n          -  Relapsing MS or Healthy Control (no neurological disorders)\n\n          -  Expanded Disability Status Scale (EDSS) scores \u22645.5\n\n          -  Disease duration <30 years\n\n          -  Normal kidney function (creatinine clearance >59 mL/min) (patients only)\n\n          -  Signed informed consent\n\n          -  None of the exclusion criteria\n\n        Exclusion Criteria:\n\n          -  MS patients with hepatic impairment\n\n          -  Nursing mothers or pregnant women who will need to undergo 12 months follow-up\n\n          -  Women of childbearing potential not using reliable contraception\n\n          -  Patients currently treated with leflunomide\n\n          -  Serum alanine aminotransferase (ALT) >1.5 times the upper limit of normal\n\n          -  A clinically significant infectious or neurological (for HC only) illness (e.g.,\n             cellulitis, abscess, pneumonia, septicemia) within 30 days prior to treatment\n             assignment\n\n          -  Unwillingness or inability to comply with the requirements of this protocol including\n             the presence of any condition (physical, mental, or social) that is likely to affect\n             the subject's ability to comply with the study protocol\n\n          -  Any other reasons that, in the opinion of the Investigator, indicate that the subject\n             is unsuitable for enrollment into this study\n\n          -  Other pathology related to MRI abnormalities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "MS patients from the Baird MS Center, The Jacobs Neurological Institute, Department of\n        Neurology, State University at Buffalo, NY, USA who are also taking Aubagio as their\n        disease modifying therapy.\n\n        Healthy controls from the general population."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881191", 
            "org_study_id": "GZ-2013-10958"
        }, 
        "intervention": {
            "arm_group_label": [
                "Aubagio MRI", 
                "Healthy controls"
            ], 
            "intervention_name": "MRI", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "multiple sclerosis", 
            "relapsing remitting", 
            "MRI", 
            "teriflunomide", 
            "aubagio", 
            "gray matter atrophy", 
            "gray matter pathology"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "ckennedy@bnac.net", 
                "last_name": "Cheryl L Kennedy, LMSW, MPH", 
                "phone": "716-859-7068"
            }, 
            "contact_backup": {
                "email": "rmelia@bnac.net", 
                "last_name": "Rebecca Melia, BS", 
                "phone": "716-859-7040"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14203"
                }, 
                "name": "Buffalo Neuroimaging Analysis Center"
            }, 
            "investigator": {
                "last_name": "Robert Zivadinov, MD,PhD, FAAN", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Effect of Teriflunomide (Aubagio\u00ae) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study", 
        "overall_contact": {
            "email": "rzivadinov@bnac.net", 
            "last_name": "Robert Zivadinov, MD,PhD,FAAN", 
            "phone": "716-859-7031"
        }, 
        "overall_contact_backup": {
            "email": "ckennedy@bnac.net", 
            "last_name": "Cheryl L Kennedy, LMSW, MPH", 
            "phone": "716-859-7068"
        }, 
        "overall_official": {
            "affiliation": "University at Buffalo", 
            "last_name": "Robert Zivadinov, MD,PhD,FAAN", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary aim of this study is to define the effect of teriflunomide  (Aubagio\u00ae) on the development of gray matter (GM) atrophy in patients with relapsing multiple sclerosis (MS) using MRI.", 
            "safety_issue": "No", 
            "time_frame": "baseline, 6 month and 12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University at Buffalo", 
            "investigator_full_name": "Robert Zivadinov, MD, PhD", 
            "investigator_title": "Director, Buffalo Neuroimaging Analysis Center, Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The secondary objective of this study is to define the effect of teriflunomide on subcortical deep gray matter (SDGM) pathology using MRI over 12 months.", 
            "safety_issue": "No", 
            "time_frame": "baseline, month 6 and month 12"
        }, 
        "source": "University at Buffalo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University at Buffalo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}